<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00595790</url>
  </required_header>
  <id_info>
    <org_study_id>IC51-304</org_study_id>
    <nct_id>NCT00595790</nct_id>
  </id_info>
  <brief_title>Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51</brief_title>
  <official_title>Phase 3 Study to Compare a Rapid Immunization Regime With the Standard Regime of IC51 as Vaccine for Japanese Encephalitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valneva Austria GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valneva Austria GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates a rapid immunization regime of the Japanese Encephalitis vaccine IC51
      (JE-PIV) in healthy subjects aged &gt; or = 18 years
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, observer blinded, controlled, randomized phase 3 study. The study
      population consists of healthy male and female volunteers, aged at least 18 years.

      Approximately 375 volunteers will be enrolled at approximately 2 to 3 sites.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SCR (Seroconversion Rate) at Day 56</measure>
    <time_frame>day 56</time_frame>
    <description>Seroconversion rate: percentage of subjects with &gt;= 1:10 anti-JEV neutralizing antibody titer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SCR at Day 10, 28 and 35</measure>
    <time_frame>Day 10, 28 and 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT at Day 10, 28, 35 and 56</measure>
    <time_frame>Day 10, 28, 35 and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Study duration</time_frame>
    <description>AEs, Local and systemic tolerability, Safety laboratory parameters</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">374</enrollment>
  <condition>Japanese Encephalitis</condition>
  <arm_group>
    <arm_group_label>IC51 2 x 6 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 x 6 mcg (microgram)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC51 1 x 12 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 x 12 mcg (microgram)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC51 1 x 6 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 x 6 mcg (microgram)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IC51</intervention_name>
    <arm_group_label>IC51 2 x 6 mcg</arm_group_label>
    <arm_group_label>IC51 1 x 12 mcg</arm_group_label>
    <arm_group_label>IC51 1 x 6 mcg</arm_group_label>
    <other_name>Japanese Encephalitis purified inactivated vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Written informed consent obtained prior to study entry

        Exclusion Criteria:

          -  History of clinical manifestation of any flavivirus infection

          -  History of vaccination against Japanese encephalitis (JE), Yellow fever and Dengue
             fever (an anti-JEV neutralizing antibody titer &gt;= 1:10 at baseline is acceptable for
             inclusion, these subjects will be part of the safety population, but will not be
             analyzed for immunogenicity in the per-protocol analysis)

          -  Use of any other investigational or non-registered drug or vaccine in addition to the
             study vaccine during the study period or within 30 days preceding the first dose of
             study vaccine

          -  Immunodeficiency including post-organ-transplantation or immunosuppressive therapy

          -  A family history of congenital or hereditary immunodeficiency

          -  History of autoimmune disease

          -  Any acute infections within 4 weeks prior to enrollment

          -  Infection with HIV, Hepatitis B or Hepatitis C

          -  Pregnancy, lactation or unreliable contraception in female subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Eder, Mag.</last_name>
    <role>Study Director</role>
    <affiliation>Valneva Austria GmbH</affiliation>
  </overall_official>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2008</study_first_posted>
  <results_first_submitted>December 5, 2013</results_first_submitted>
  <results_first_submitted_qc>February 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2014</results_first_posted>
  <last_update_submitted>April 9, 2014</last_update_submitted>
  <last_update_submitted_qc>April 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IC51 2 x 6 mcg</title>
          <description>2 x 6 mcg (microgram)</description>
        </group>
        <group group_id="P2">
          <title>IC51 1 x 12 mcg</title>
          <description>1 x 12 mcg (microgram)</description>
        </group>
        <group group_id="P3">
          <title>IC51 1 x 6 mcg</title>
          <description>1 x 6 mcg (microgram)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="124">124 subjects randomized to this group, 125 subjects received 1x12 mcg.(Safety Population: N=125)</participants>
                <participants group_id="P3" count="125">125 subjects randomized to this group, 124 subjects received 1x6 mcg.(Safety Population: N=124)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="123">The Participant Flow shows all study participants randomized.Prim. Outcome is based on PP Population</participants>
                <participants group_id="P2" count="123">The Participant Flow shows all study participants randomized.Prim. Outcome is based on PP Population</participants>
                <participants group_id="P3" count="122">The Participant Flow shows all study participants randomized.Prim. Outcome is based on PP Population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IC51 2 x 6 mcg</title>
          <description>2 x 6 mcg (microgram)</description>
        </group>
        <group group_id="B2">
          <title>IC51 1 x 12 mcg</title>
          <description>1 x 12 mcg (microgram)</description>
        </group>
        <group group_id="B3">
          <title>IC51 1 x 6 mcg</title>
          <description>1 x 6 mcg (microgram)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
            <count group_id="B2" value="125"/>
            <count group_id="B3" value="124"/>
            <count group_id="B4" value="374"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.6" spread="14.2"/>
                    <measurement group_id="B2" value="41.2" spread="15.0"/>
                    <measurement group_id="B3" value="41.6" spread="14.8"/>
                    <measurement group_id="B4" value="40.8" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Baseline Characteristics are based on Safety Population: all randomized subjects who received at least one vaccination, analysed using the treatment actually received.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SCR (Seroconversion Rate) at Day 56</title>
        <description>Seroconversion rate: percentage of subjects with &gt;= 1:10 anti-JEV neutralizing antibody titer</description>
        <time_frame>day 56</time_frame>
        <population>The Participant Flow shows all study participants randomized. The Primary Outcome is based on the Per-Protocol-Population (all randomized subjects without major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>IC51 1 x 12 mcg</title>
          </group>
          <group group_id="O2">
            <title>IC51 2x6 mcg</title>
          </group>
          <group group_id="O3">
            <title>IC51 1x6 mcg</title>
          </group>
        </group_list>
        <measure>
          <title>SCR (Seroconversion Rate) at Day 56</title>
          <description>Seroconversion rate: percentage of subjects with &gt;= 1:10 anti-JEV neutralizing antibody titer</description>
          <population>The Participant Flow shows all study participants randomized. The Primary Outcome is based on the Per-Protocol-Population (all randomized subjects without major protocol deviation</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" lower_limit="32.2" upper_limit="50.3"/>
                    <measurement group_id="O2" value="97.3" lower_limit="94.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="25.6" lower_limit="17.7" upper_limit="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Assessment of non-inferiority of IC51 1x12 mcg vs. IC51 2x6 mcg at Day 56 based on the difference (IC51 1x12 mcg - IC51 2x6 mcg) in SCRs in the PP population. Non-inferiority of IC51 1 x 12 mcg compared to IC51 2 x 6 mcg was accepted if the lower limit of the 95% CI of the adjusted for center SCR difference (IC51 1 x 12 mcg - IC51 2 x 6 mcg) was higher than the noninferiority margin at -10%.</non_inferiority_desc>
            <p_value>&gt;0.99</p_value>
            <method>Mantel Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SCR at Day 10, 28 and 35</title>
        <time_frame>Day 10, 28 and 35</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT at Day 10, 28, 35 and 56</title>
        <time_frame>Day 10, 28, 35 and 56</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety</title>
        <description>AEs, Local and systemic tolerability, Safety laboratory parameters</description>
        <time_frame>Study duration</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IC51 2 x 6 mcg</title>
          <description>2 x 6 mcg (microgram)</description>
        </group>
        <group group_id="E2">
          <title>IC51 1 x 12 mcg</title>
          <description>1 x 12 mcg (microgram)</description>
        </group>
        <group group_id="E3">
          <title>IC51 1 x 6 mcg</title>
          <description>1 x 6 mcg (microgram)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="125"/>
                <counts group_id="E2" events="31" subjects_affected="27" subjects_at_risk="125"/>
                <counts group_id="E3" events="26" subjects_affected="22" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Fatique</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="125"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="125"/>
                <counts group_id="E2" events="41" subjects_affected="37" subjects_at_risk="125"/>
                <counts group_id="E3" events="40" subjects_affected="36" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="40" subjects_affected="30" subjects_at_risk="125"/>
                <counts group_id="E2" events="49" subjects_affected="34" subjects_at_risk="125"/>
                <counts group_id="E3" events="51" subjects_affected="34" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Manager Clinical Research</name_or_title>
      <organization>Intercell AG</organization>
      <phone>+43 1 206 20 ext 0</phone>
      <email>kdubischar-kastner@intercell.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

